Product Details

Verified Reactivity

Human, Cynomolgus, Rhesus

Reported Reactivity

Chimpanzee

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

Human peripheral T cells

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510? under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Brilliant Violet 510? excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510? is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding.　Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317453 and 317454).

In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.⁹

Application References

(PubMed link indicates BioLegend citation)

1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061.
3. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
4. Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed
5. Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36.
6. Linder J, et al. 1987. Am. J. Pathol. 127:1.
7. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC)
8. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen)
9. Lederman S, et al. 1991. Mol Immunol. 28:1171-81.

Product Citations

1. Carre C, et al. 2021. iScience. 24:102970. PubMed
2. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
3. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
4. Wang M, et al. 2022. Immun Inflamm Dis. 10:e626. PubMed
5. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
6. Peng S et al. 2019. Cell Rep. 28(10):2728-2738 . PubMed
7. Kasper M, et al. 2021. Elife. 10:. PubMed
8. Vijayakumar B, et al. 2022. Immunity. . PubMed
9. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
10. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
11. Guedan S, et al. 2018. JCI Insight. 3. PubMed
12. Priyanto H, et al. 2021. J Clin Tuberc Other Mycobact Dis. 22:100214. PubMed
13. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
14. Heger L, et al. 2018. Front Immunol. 9:744. PubMed
15. Tu HA, et al. 2020. Cell Rep Med. 1:100155. PubMed
16. Breen EC, et al. 2022. iScience. 25:104488. PubMed
17. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
18. Idorn M, et al. 2018. Oncoimmunology. 7:e1412029. PubMed
19. Khaitan A, et al. 2016. PLoS One. 11: 0161786. PubMed
20. Lundtoft C, et al. 2017. PLoS Pathogens. 13(6):e1006425. PubMed
21. De Domenico E, et al. 2020. STAR Protoc. 1:100233. PubMed
22. Meckiff BJ, et al. 2020. Cell. 183(5):1340-1353.e16. PubMed
23. Wing A, et al. 2018. Cancer Immunol Res. 6:605. PubMed
24. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
25. Riese P, et al. 2022. Nat Commun. 13:6894. PubMed
26. Menges D, et al. 2022. Nat Commun. 13:4855. PubMed
27. Willmann K, et al. 2014. Nat Commun. 5:5360. PubMed
28. Festag J, et al. 2020. Mol Ther Nucleic Acids. 1.330555556. PubMed
29. Castellarin M, et al. 2020. JCI Insight. 5:00. PubMed
30. Kaiser FMP, et al. 2021. J Allergy Clin Immunol. 147:391. PubMed
31. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
32. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
33. Diamantopoulos PT, et al. 2022. Cancers (Basel). 14:. PubMed
34. Steindor M, et al. 2015. PLoS One. 10:119737. PubMed
35. Todnem Sakkestad S, et al. 2019. Pathogens. 8. PubMed
36. Kenswil KJG, et al. 2021. Exp Hematol. S0301-472X:00426. PubMed
37. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
38. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed

RRID

AB_2561377 (BioLegend Cat. No. 317443) AB_2561866 (BioLegend Cat. No. 317444)